Literature DB >> 7295471

Metabolism and pharmacokinetics of dothiepin.

K P Maguire, G D Burrows, T R Norman, B A Scoggins.   

Abstract

1 Seven healthy volunteers received a single oral dose of 75 mg dothiepin. Plasma concentrations of dothiepin were measured by gas chromatography-mass fragmentography. 2 The plasma concentrations obtained were fitted to the equation Ct = Ae-a(t-tau) + Be-beta(t-tau) - Ce-ka(t-tau). The mean peak concentration was 47(33-71) microgram/l at 3(2-5) h. Mean estimates were as follows: absorption half life 1.2(0.07-3.0) h, distribution half-life 2.6(1.1-3.8) h, elimination half-life 22(14-40) h, apparent volume of distribution 45(20-92) l/kg, and oral clearance 1.36(0.88-1.8) l kg-1 h-1. 3 Blood concentrations of dothiepin were measured in comparison in five of the volunteers. The mean blood/plasma ratio was 0.7(0.6-0.8). 4 Plasma and blood concentrations of northiaden and blood concentrations of dothiepin S-oxide, two metabolites of dothiepin, were also measured. Dothiepin S-oxide was the major metabolic reaching a peak level of 81(34-150) microgram/l at 5(4-6) h. In comparison, northiaden reached a peak concentration of only 10 (3-21) microgram/l at 5 (4-9) h. The mean half-life of elimination of dothiepin S-oxide was 19 (13-35) h while that for northiaden was 33 (22-60) h.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295471      PMCID: PMC1401810          DOI: 10.1111/j.1365-2125.1981.tb01235.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  The metabolism of dothiepin hydrochloride in vivo and in vitro [proceedings].

Authors:  E L Crampton; W Dickinson; G Haran; B Marchant; P C Risdall; P A Berry
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

2.  First-pass metabolism of nortriptyline in man.

Authors:  L F Gram; K F Overo
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  A comparison between dothiepin and doxepin in the treatment of depression.

Authors: 
Journal:  Practitioner       Date:  1976-05

4.  Simultaneous measurement of dothiepin and its major metabolites in plasma and whole blood by gas chromatography-mass fragmentography.

Authors:  K P Maguire; T R Norman; G D Burrows; B A Scoggins
Journal:  J Chromatogr       Date:  1981-03-13

5.  An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.

Authors:  K P Maguire; T R Norman; G D Burrows; B A Scoggins
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

  5 in total
  7 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 3.  Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  S G Lancaster; J P Gonzalez
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 4.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

5.  Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations.

Authors:  K P Maguire; T R Norman; I McIntyre; G D Burrows
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 7.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.